Upperson Pharma Solutions, a contract development and manufacturing organization (CDMO), has expanded its oral dosage form capabilities at its newly built headquarters in Nottingham, UK.

Part of Upperton’s £15m investment program announced in January, the state-of-the-art facility has benefited from a significant investment in large, commercial scale equipment offering powder blending up to 250kg per batch, capsule filling up to 40,000 capsules/hour, dry granulation processing up to 100kg/hour and tablet pressing up to 120,000 tablets/hour.

The company said that expanded capabilities will enable Upperton to continue to meet the growing demand for its oral, nasal, and pulmonary dosage form development and GMP manufacturing services, as well as increase its ability to support larger scale, later stage development.

New equipment is currently being installed and commissioned in a dedicated 700 sq. ft. cleanroom which is one of 10 GMP suites housed in Upperton’s 50,000 sq.ft. facility expected to be fully operational by the end of 2023.

“This investment is a pivotal next step as we move towards the completion of our new facility,” said Upperton CEO Nikki Whitfield. “It will enable us to extend our support for our clients’ manufacturing needs from early development phases through to Phase III clinical trials, registration batches and subsequent commercial manufacture, all at one, single site.”

Upperton’s new £15m, 50,000 sq. ft. facility in Nottingham has been designed to handle highly potent molecules and controlled drugs and will allow a significant increase in research and development laboratory space alongside a 10-fold increase in GMP manufacturing space.

Whitfield added, “We are delighted with the progress we have made. The investment allows us to increase our current development and manufacturing capacity as well as expand our solid dose and spray drying offerings to address the growing needs of our customers. We will also be able to support existing and new clients further in their product development journey, ensuring a consistent and streamlined pathway to approval from product development through to late stage and commercial.”